Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures - Homepage
Triathlon Medical Ventures - Team
Triathlon Medical Ventures - Investment Focus
Triathlon Medical Ventures - Investment Strategy
Triathlon Medical Ventures - Investment Criteria
Contact Triathlon Medical Ventures - Evaluation Process
Triathlon Medical Ventures - Portfolio
Triathlon Medical Ventures - News
Triathlon Medical Ventures - Links
Contact Contact Triathlon Medical Ventures

Triathlon Medical Ventures

 

 

 

 

 

National Venture Capital Association 2008-2009 Member


Whether you're an entrepreneur or a venture capitalist, you'll find a warm welcome at Triathlon Medical Ventures. Prior to opening our doors in 2004, Triathlon's team has been investing in life science business opportunities for more than fifteen years. And we are also industry veterans, experienced at growing medical device and biotechnology companies from the inside out - as owners, directors and operational managers.

Triathlon Medical Ventures is a Midwest-based venture capital firm that invests exclusively in the life sciences. We provide equity capital to early and expansion stage companies with proprietary biomedical technology platforms or products addressing significant human healthcare needs.

We are geographically focused on early stage opportunities in the Midwest but will also invest in later stage companies nationwide. We are headquartered in Cincinnati, with offices and partners in Indianapolis and Louisville. The partners are industry veterans with extensive experience as both operational managers and venture capitalists.

We invite you now to explore these web pages and consider how Triathlon Medical Ventures might be the right partner for your investment opportunity.



RECENT NEWS

Click here for Triathlon Medical Ventures related videos on YouTube

May 3, 2011
Akebia Therapeutics, Inc. Announces Successful Completion of Single Ascending Dose Phase 2A Pilot Study of AKB-6548 For Anemia


April 26, 2011
Akebia Therapeutics, Inc. Completes $22M Series B Financing


April 26, 2011
Endocyte Announces Intent to Seek Conditional Marketing Authorization in the European Union for Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 for Platinum-Resistant Ovarian Cancer


April 26, 2011
Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure


February 9, 2011
Endocyte Announces Closing of Initial Public Offering and Over-allotment Option


January 24, 2011
Amgen to Acquire BioVex, A Privately Held Biotechnology Company Headquartered In Woburn, Mass


January 3, 2011
Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia


August 30, 2010
Endocyte Secures $15 Million Credit Facility


August 17, 2010
Endocyte Files Registration Statement with SEC for Initial Public Offering


August 2, 2010
BioVex Announces Publication of Head and Neck Cancer Clinical Trial Results with OncoVEXGM-CSF in the Journal Clinical Cancer Research


July 22, 2010
BioVex Appoints Ex Roche Oncology Head, Kapil Dhingra, to the Board of Directors


July 1, 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer


 
 
Copyright © 2004 - Triathlon Medical Ventures - All Rights Reserved Web Site Credits Legal Notices & Privacy Policy